Shares of Freeline Therapeutics Holdings plc (FRLN) are gaining over 10% on Wednesday morning after the company reported positive initial clinical data from first cohort of phase 1/2 trial of FLT201, its novel gene therapy candidate in Gaucher disease.
CHI Advisors LLC cut its holdings in Freeline Therapeutics Holdings plc (NASDAQ:FRLN – Free Report) by 1.8% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 4,729,419 shares of the company’s stock after selling 85,000 shares during the period. Freeline Therapeutics comprises approximately 0.6% of CHI Advisors […]